Ask AI
ProCE Banner Series

Integrating Novel Mechanisms in Relapsed/Refractory Multiple Myeloma

This program will explore the role of novel mechanisms of action in later-line therapy, with particular emphasis on the clinical profile and practical integration of selinexor-based regimens. The discussion will review key clinical trial data supporting selinexor in combination strategies and consider how these findings inform sequencing decisions in an increasingly complex therapeutic environment.

In addition to pivotal data, the program will address real-world considerations such as patient selection, tolerability management, dose optimization strategies, and positioning relative to other available classes.

Key Takeaways

  • Review the current treatment landscape for relapsed/refractory multiple myeloma and the role of novel mechanisms of action
  • Discuss key clinical data supporting selinexor-based regimens, including efficacy and safety considerations
  • Consider practical strategies for patient selection, adverse event management, and sequencing within the broader myeloma treatment paradigm

All Events

Integrating Novel Mechanisms in Relapsed/Refractory Multiple Myeloma

Upcoming Events

April

08

2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual